Prorestan

Prorestan is a fictional synthetic progestin described in educational resources to illustrate progesterone receptor signaling. It is not a marketed drug and has no approval in real-world medicine.

Chemistry: Prorestan is depicted as a steroidal molecule based on the gonane framework, with substitutions typical of progestins that confer high affinity for progesterone receptors. In the fictional descriptions, it features a 3-keto group and a persistent C-4 double bond, with substituents aimed at receptor selectivity and oral bioavailability.

Pharmacology: In vitro studies presented for Prorestan show high affinity for both PR-A and PR-B isoforms and robust progestogenic activity in cellular assays. It is described as having low affinity for androgen, estrogen, and mineralocorticoid receptors, though a moderate interaction with glucocorticoid receptors is sometimes noted in hypothetical models. In animal models, Prorestan reduces endometrial proliferation and induces secretory changes consistent with progestin action.

History and uses: Prorestan is described in fictional pharmacology texts as developed in the early 2010s for teaching and simulation purposes, and has not progressed to clinical trials or regulatory evaluation. It is used to illustrate structure–activity relationships and receptor binding in coursework and digital simulations.

Safety and regulatory status: As a fictional compound, Prorestan has no real-world pharmacovigilance data, no approved indications, and no established dosing or safety profile. Hypothetical risk discussions focus on common progestin-associated effects such as metabolic changes, mood effects, and endometrial impacts.

See also: Progestins, Progesterone receptor, Steroid hormone.